To date, 4 anti‐EGFR monoclonal antibodies named cetuximab, panitumumab, necitumumab, and nimotuzumab have been approved for clinical use,[113] normally used in the head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (mCRC), and other solid tumors. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.